homeplatform • prevention
SARS-CoV-2 being destroyed

COVID-19 Vaccine

Our COVID-19 vaccine is in Phase 3 clinical trials. It is based on a proven adjuvanted recombinant protein design, similar to that of the highly successful Hepatitis B vaccine, which targets a segment of the SARS-CoV-2 spike protein.

Key differentiators:

Universal Coronavirus Vaccine Therapeutics

Universal Coronavirus Vaccine & Therapeutics

Together with our partners, we are leveraging extensive intellectual property and development platforms to advance research, development, and commercialization of a universal coronavirus vaccine as a core component of the Nano Immunity Platform.

We are also exploring a range of design and delivery methodologies, including mRNA and recombinant protein, as well as monoclonal antibody-based therapeutics.

Novel Vaccine
Delivery Mechanisms

We are developing towards a range of alternative, more versatile and affordable vaccine delivery mechanisms, to enable direct to consumer accessibility on a global scale.